Nuclear factor kappa B subunit 1 (NFKB1) (NFKB1)

Nuclear factor kappa B subunit 1 (NFKB1) is a pivotal transcription factor and a key component of the canonical NF-κB signaling pathway, which serves as a master regulator of the body's immune and inflammatory responses (UniProt P19838; Wikipedia). It is synthesized as a 105 kDa precursor (p105) that undergoes proteasomal processing to generate the active 50 kDa subunit (p50), which typically forms heterodimers with other Rel family proteins like RelA/p65 to regulate gene expression (GeneCards NFKB1; PubMed 1.3.2). Upon activation by stimuli such as cytokines (TNF-α, IL-1) or pathogens, the IκB kinase (IKK) complex phosphorylates inhibitory IκB proteins, leading to their degradation and the subsequent nuclear translocation of NF-κB dimers (NIH 1.2.1; Wikipedia). This pathway is frequently constitutively active in various cancers, including multiple myeloma and lymphoma, where it promotes cell survival and resistance to apoptosis (NIH 1.2.3; PubMed 1.3.1). Therapeutic targeting of the NF-κB pathway is clinically established through proteasome inhibitors like bortezomib, which prevent IκB degradation, though such treatments are often limited by significant safety concerns such as severe immunosuppression and systemic toxicity due to the pathway's broad physiological roles (NIH 1.2.5; Frontiers 1.4.3).

Other names

p105p50Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1KBF1EBP-1CVID12NF-kappa-B1NF-kB1NF-kappaBNFKB-p105NFKB-p50

Inhibition of the proteasome to prevent IκB degradation, inhibition of IκB kinase (IKK) activity, and direct inhibition of NF-κB subunit DNA binding or nuclear translocation.